Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Monosodium inosinate is a sodium salt of inosine monophosphate (IMP), a naturally occurring nucleotide. It is widely known as a food additive used as a flavor enhancer, particularly for providing the umami taste. In a clinical context, it is being investigated for its potential to treat xerostomia (dry mouth) by stimulating salivary flow. Its mechanism of action involves the activation of umami taste receptors, specifically the T1R1/T1R3 heterodimer, which triggers a gustatory-salivary reflex. Research conducted by Okayama University Hospital has explored its efficacy in healthy adults to evaluate changes in salivation flow following intraoral administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on monosodium inosinate.